about
Poxvirus pathogenesisVaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replicationImmune response in rabbits to surface components of extracellular and intracellular forms of vaccinia virus.In vitro assessment of cellular immunity to vaccinia virus: contribution of lymphocytes and macrophagesUse of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.Smallpox vaccines: targets of protective immunity.Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus.A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors.The immune response to infection with vaccinia virus in mice. II. Appearance of hypersensitivity, production of macrophage migration inhibitory factor and transformation of spleen cells in response to virus antigensThe immune response to infection with vaccinia virus in mice. I. Infection and the production of antibody neutralizing cell-associated and cell-free virusExtracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress.Effect of glycosylation inhibitors on the release of enveloped vaccinia virus.Adsorption and penetration of enveloped and naked vaccinia virus particles.Polypeptide composition of extracellular enveloped vaccinia virus.Effect of development and aging on the response of canine lymphocytes to phytohemagglutinin.A comparison of the antigens present on the surface of virus released artificially from chick cells infected with vaccinia virus, and cowpox virus and its white pock mutantCharacterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.Inactivated smallpox vaccine. A comparison of inactivation methods.Intranasal monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe monkeypox virus disease.
P2860
Q24634729-2A569B80-E4A2-4289-BE10-61EF7530BCFAQ30540518-5D7C1EE6-4903-49C6-A055-7CA25B981A15Q33907414-C9D5B955-A088-4F8A-A7FD-F6B43FB32E7EQ34163533-0C76D1EB-379F-43DE-A66C-60D930F536D2Q34196187-9937F7B1-F8A3-4EB3-8117-ECEC83E58E92Q34780607-E889F6DA-4378-4FED-AA72-230409A9A978Q35853542-BFF43F6C-71AE-430E-B2F7-638F6EF9B212Q35884079-D98FF522-DAE6-43B5-98AC-206D70A53759Q36252234-7D58C73D-78D3-4B49-B07C-BA860B24DE74Q36252256-04AB59F2-0FE1-4675-AD88-C705AA4963D6Q36496450-043FEF6D-391A-47EF-AE9C-012F5267EEE3Q40064533-E1CBA345-D40B-4051-A5AA-1AD1D54B47BFQ40145028-072C12E6-931D-43D9-BF29-1FC40DE9AE54Q40626374-AA33376F-8202-41CA-81FA-E8ECCE02A3F1Q40626379-224974F9-AA5D-40A3-9519-262BDAD2A365Q40915991-0456CB44-348F-42F0-925E-A269388261A7Q42036461-B3713FC9-F862-4A9B-9BCB-F353D4B83E6BQ42633733-D0EEBC93-26C5-4778-8D48-74DD1470A715Q42791830-31878978-5142-491A-9D27-E067C960DDBDQ55714396-89DACD5E-C3C3-46D8-BB6B-C544953D7C98
P2860
description
1969 nî lūn-bûn
@nan
1969年の論文
@ja
1969年論文
@yue
1969年論文
@zh-hant
1969年論文
@zh-hk
1969年論文
@zh-mo
1969年論文
@zh-tw
1969年论文
@wuu
1969年论文
@zh
1969年论文
@zh-cn
name
Protection against poxviruses.
@en
type
label
Protection against poxviruses.
@en
prefLabel
Protection against poxviruses.
@en
P1476
Protection against poxviruses
@en
P2093
Boulter EA
P2860
P304
P407
P577
1969-03-01T00:00:00Z